Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC

0
129
In this phase II, double-blind, placebo-controlled trial, investigators randomly assigned patients with unresectable epidermal growth factor receptor-mutated stage III NSCLC without progression during or after chemoradiotherapy to receive osimertinib or placebo until disease progression occurred or the regimen was discontinued.
[New England Journal of Medicine]
Abstract